A detailed history of Pinnacle Financial Partners Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Pinnacle Financial Partners Inc holds 6,641 shares of VRTX stock, worth $3.11 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
6,641
Previous 612 985.13%
Holding current value
$3.11 Million
Previous $286,000 979.72%
% of portfolio
0.06%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$460.0 - $505.78 $2.77 Million - $3.05 Million
6,029 Added 985.13%
6,641 $3.09 Million
Q2 2024

Aug 06, 2024

BUY
$392.81 - $485.53 $7,856 - $9,710
20 Added 3.38%
612 $286,000
Q1 2024

Apr 30, 2024

SELL
$407.69 - $446.08 $20,384 - $22,304
-50 Reduced 7.79%
592 $247,000
Q4 2023

Jan 22, 2024

BUY
$343.0 - $410.68 $220,206 - $263,656
642 New
642 $261,000
Q2 2023

Aug 07, 2023

BUY
$314.42 - $351.91 $188,652 - $211,146
600 New
600 $211,000
Q1 2022

May 02, 2022

SELL
$221.42 - $260.97 $230,055 - $271,147
-1,039 Closed
0 $0
Q4 2021

Feb 01, 2022

BUY
$177.01 - $223.45 $183,913 - $232,164
1,039 New
1,039 $229,000
Q2 2021

Jul 21, 2021

SELL
$187.49 - $221.1 $174,928 - $206,286
-933 Closed
0 $0
Q1 2021

Apr 19, 2021

SELL
$207.02 - $241.31 $17,389 - $20,270
-84 Reduced 8.26%
933 $200,000
Q4 2020

Jan 13, 2021

SELL
$207.01 - $276.09 $62,931 - $83,931
-304 Reduced 23.01%
1,017 $240,000
Q3 2020

Oct 27, 2020

BUY
$255.65 - $303.1 $1,533 - $1,818
6 Added 0.46%
1,321 $360,000
Q2 2020

Jul 28, 2020

BUY
$225.48 - $295.8 $296,506 - $388,977
1,315 New
1,315 $382,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Pinnacle Financial Partners Inc Portfolio

Follow Pinnacle Financial Partners Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Financial Partners Inc, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Financial Partners Inc with notifications on news.